braindata scientist


Connecting the dots to reveal the bigger picture...

Download Brochure
scroll to see more

265 382

Analyses Challenges

thousands of analyses carried out in few weeks time on high-quality dedicated resources, instead of years on regular computers

118 328

Imaging Datasets

about 8 000 patients’ scans at your disposal to design large-scale clinical trials, studies and benchmark your innovative new applications

186

Users Wordwide

join and benefit from our international database of users, whether being from pharma industry, private sector, clinical research or neuroscientist

40

Data Mining Toolkits

enjoy access to state-of-the-art imaging and data mining applications, all in one place where you can setup and test new analyses on large samples of data

Services

quickly crunch into your big data


datastrategy

Our data scientists will assist you in devising new strategies to make the best out of your data, from a simple diagnostic, to a complete feasibility study.

  • Audit, diagnostic
  • Feasibility study
  • Data Scientist consulting

datacollection

Our data experts will help you with sourcing, preparing optimally your data, enriching and curating it for your particular analyses.

  • Sourcing
  • Quality Control
  • Enrichment
  • Curation

dataAnalysis

Utilising the most powerful computing platform in the field, our data scientists will support you in selecting feature extraction and processing algorithms to solve your pressing scientific questions.

  • Analytics strategy
  • Quality Control
  • Processing
  • Benchmarking
  • Data Scientist support

datapresentation

Our data scientists will simplify, illustrate your analysis outcomes with powerful visualisation and reporting techniques.

  • Interpretation
  • Visualization
  • Reporting

references

cerebro is a spin-off company of theneugrid initiative


Opening perspectives

cerebro has been designed in the EU and is operated from Switzerland. It bundles high quality services and scientific expertise. cerebro is a partner of campus biotech and a member of the bioalps life science cluster of western Switzerland.

 swiss_made-300x300logoBioAlps_new2  campus

See what we do for…


See result
See below
01. pharma industry

pharmaA Pharmaceutical company has historical data from a failed clinical trial of a monoclonal antibody in Alzheimer’s disease whose post-hoc analyses might provide precious information on the mechanism of action of the class of drugs. CEREBRO personnel develop design an experiment on 2.500 high-resolution MR scans and 1.000 amyloid PET scans of treated and placebo patients scanned at baseline and 3 time points over the duration of the trial. The cortical thickness is extracted in the neuGRID environment with the CIVET and FREESURFER pipelines. Statistical analysis shows that the paradoxical greater cortical thinning in treated patients map in the regions of greater amyloid load, confirming that the previously unexplained finding is due to energetic amyloid removal rather than aspecific mechanisms (e.g. shift of water among compartments). Results are neatly presented by CEREBRO and used by the company to internally discuss the future of its €800M worth research line on monoclonal antibodies.

02. Developers

developers

A software developer has implemented a new algorithm for the assessment of hippocampal atrophy on T1-weighted MR scans. Thanks to CEREBRO’s Web portal he can validate his algorithm on large datasets by exploiting the computational resources of the underlying platform. Once validated, the new algorithm can be exposed to other CEREBRO users to enhance visibility and spread its use in the scientific and clinical community.

03. Clinicians

clinicians

A clinician is interested in extracting imaging markers of Alzheimer’s disease out of brain FDG-PET and structural MR scans (i.e. posterior cortical hypometabolism and hippocampal atrophy) and confirm or disprove the findings of the neurorardiologist’s and nuclear medic’s visual assessment reports. The clinician can log onto CEREBRO’s web portal, easily upload the scans, run a number of specifically designed tools, and receive a report in his/her email account.

04. neuroscientists

neuro

A Pharmaceutical company has historical data from a failed clinical trial on monoclonal antibody in Alzheimer’s disease whose post-hoc analyses might provide precious information on the mechanism of action of the class of drugs. CEREBRO develops an experiment for extracting cortical thickness on 2.500 high-resolution MR scans and 1.000 amyloid PET scans of (treated and placebo) patients followed for the duration of the trial. Statistical analysis shows that the paradoxical greater cortical thinning in treated patients map in the regions of greater amyloid load, confirming that the previously unexplained finding is due to energetic amyloid removal rather than a specific mechanisms (e.g. shift of water among compartments)

Founders

mobilise our data scientists at your convenience


DR. David Manset

DR. David Manset

Founder & President CEO

CEREBRO is the next generation clinical trials and validations data science toolset

PROF. & M.D. Giovanni Frisoni

PROF. & M.D. Giovanni Frisoni

Founder & CEO

CEREBRO will be the Google+ of medical data analysis, where + stands for human top class scientific expertise

DR. Jerome Revillard

DR. Jerome Revillard

Founder & CTO

CEREBRO blends an unique infrastructure and expertise to discover and improve brain diseases diagnosis and treatments

PROF. Lars-Olof Wahlund

PROF. Lars-Olof Wahlund

Founder

CEREBRO is the optimal way for big data in neuroimaging

contact

get in touch with our experts




 

CEREBRO GmbH

Rue De-Candolle 11,
1205 Genève, Suisse

contact@cerebro.pro / LinkedIn

+41  79 137 42 55